Dr. Uri Lopatin

Uri Lopatin, M.D. is a Physician-Scientist, Board Certified Internist and Infectious Disease Specialist, and a Senior Director for Clinical and Translational research in liver diseases at Gilead Sciences.
 
Uri completed his Medical Internship at the University of Washington in Seattle, his Residency at NYU Medical Center in New York, and his Infectious Disease Fellowship at the National Institute of Allergy and Infectious Diseases (NIH). After working on viral mucosal immunology at the NIH, he entered the pharmaceutical industry to work on novel therapies for Hepatitis, some of which are entering clinical practice this year.
 
Until recently, he was a Translational Medical Leader at Roche Palo Alto. His team worked to define and expand the role of translational research in pharmaceutical development for Hepatitis B and C, and was privileged to be part of pioneering work in novel HCV therapeutic and pharmacogenomics programs.
 
Uri coauthored Severe Community-Onset Pneumonia in Healthy Adults Caused by Methicillin-Resistant Staphylococcus aureus Carrying the Panton-Valentine Leukocidin Genes, Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression, Autoimmune Lymphoproliferative Syndrome: A Syndrome Associated with Inherited Genetic Defects That Impair Lymphocytic Apoptosis—CT and US Features, and Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial.
 
Read CRTP Revisited: An Alumnus Perspective. Read his LinkedIn profile.